Inspire Medical Systems Inc

Inspire Medical Systems Inc (NYSE: INSP) is a medical technology company headquartered in Golden Valley, Minnesota, United States. Founded in 2007 as a spin-off from Medtronic Inc., Inspire Medical Systems became a public company in May 2018. As of December 31, 2025, the company reported approximately 1,333 employees and a trailing twelve-month revenue of $915 million.

The company specializes in developing and commercializing minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its flagship product is the proprietary Inspire therapy, an FDA-approved neurostimulation technology. This closed-loop system involves a surgically implanted device that continuously monitors a patient's breathing patterns and delivers mild stimulation to the hypoglossal nerve to maintain an open airway during sleep. The Inspire system is controlled by the patient using a remote and integrated with an app for tracking sleep goals. Inspire sells its system to hospitals and ambulatory surgery centers in the U.S., select European countries, and Japan, with distribution in Singapore and Hong Kong.

In terms of patent litigation, Inspire Medical Systems Inc appears in two tracked cases as a defendant, both at the Patent Trial and Appeal Board (PTAB), brought by Unified Patents. This posture suggests the company is primarily an operating company defending its intellectual property against challenges, rather than asserting patents as a plaintiff.

Beyond patent matters, Inspire Medical Systems Inc has also been involved in securities class action lawsuits. These lawsuits, filed in the U.S. District Court for the District of Minnesota and the Southern District of New York, allege that the company and certain executives made misleading statements regarding the launch of their Inspire V device, leading to a significant drop in stock price. Additionally, in May 2025, Inspire Medical Systems Inc initiated a patent infringement lawsuit against Nyxoah Inc in the U.S. District Court for the District of Delaware, alleging infringement on three of its patents as Nyxoah planned to enter the U.S. market. Nyxoah subsequently filed a countersuit in September 2025, claiming Inspire's Inspire IV and Inspire V devices infringe on three of Nyxoah's patents.